Empowered Funds LLC Purchases 625 Shares of Gilead Sciences, Inc. $GILD

Empowered Funds LLC lifted its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 0.3% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 220,129 shares of the biopharmaceutical company’s stock after acquiring an additional 625 shares during the quarter. Empowered Funds LLC’s holdings in Gilead Sciences were worth $24,406,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in GILD. Activest Wealth Management raised its holdings in Gilead Sciences by 2,837.5% during the 1st quarter. Activest Wealth Management now owns 235 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 227 shares during the last quarter. GoalVest Advisory LLC raised its stake in shares of Gilead Sciences by 7,566.7% during the second quarter. GoalVest Advisory LLC now owns 230 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 227 shares during the last quarter. Harbor Asset Planning Inc. acquired a new position in Gilead Sciences in the second quarter valued at approximately $27,000. Putney Financial Group LLC boosted its stake in Gilead Sciences by 53.4% in the second quarter. Putney Financial Group LLC now owns 270 shares of the biopharmaceutical company’s stock valued at $30,000 after acquiring an additional 94 shares during the last quarter. Finally, Colonial Trust Advisors boosted its stake in Gilead Sciences by 304.3% in the first quarter. Colonial Trust Advisors now owns 283 shares of the biopharmaceutical company’s stock valued at $32,000 after acquiring an additional 213 shares during the last quarter. Institutional investors and hedge funds own 83.67% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on the company. Rothschild & Co Redburn increased their price target on Gilead Sciences from $143.00 to $153.00 in a research note on Monday, November 10th. JPMorgan Chase & Co. increased their target price on Gilead Sciences from $145.00 to $150.00 and gave the company an “overweight” rating in a research note on Friday, October 31st. Wells Fargo & Company boosted their target price on Gilead Sciences from $140.00 to $145.00 and gave the stock an “overweight” rating in a research report on Friday, October 31st. The Goldman Sachs Group increased their price target on shares of Gilead Sciences from $108.00 to $110.00 and gave the company a “neutral” rating in a research report on Friday, October 31st. Finally, Sanford C. Bernstein reissued an “outperform” rating on shares of Gilead Sciences in a research note on Monday, November 3rd. Two research analysts have rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $129.13.

Gilead Sciences Trading Down 0.7%

NASDAQ:GILD opened at $124.09 on Tuesday. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.32 and a quick ratio of 1.15. The business’s 50-day simple moving average is $117.61 and its 200-day simple moving average is $113.02. Gilead Sciences, Inc. has a fifty-two week low of $86.08 and a fifty-two week high of $127.68. The stock has a market capitalization of $153.96 billion, a PE ratio of 24.72, a price-to-earnings-growth ratio of 0.81 and a beta of 0.32.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.16 by $0.31. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The business had revenue of $7.77 billion during the quarter, compared to analysts’ expectations of $7.42 billion. During the same period in the prior year, the business earned $2.02 EPS. Gilead Sciences’s revenue for the quarter was up 3.0% compared to the same quarter last year. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. Sell-side analysts expect that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 30th. Investors of record on Monday, December 15th will be issued a dividend of $0.79 per share. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.5%. The ex-dividend date is Monday, December 15th. Gilead Sciences’s dividend payout ratio (DPR) is presently 48.99%.

Insider Activity at Gilead Sciences

In other news, insider Johanna Mercier sold 3,000 shares of the business’s stock in a transaction dated Wednesday, October 15th. The stock was sold at an average price of $118.08, for a total value of $354,240.00. Following the sale, the insider directly owned 110,193 shares in the company, valued at $13,011,589.44. The trade was a 2.65% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Deborah H. Telman sold 53,646 shares of the company’s stock in a transaction dated Wednesday, November 12th. The stock was sold at an average price of $122.85, for a total value of $6,590,411.10. Following the transaction, the executive vice president directly owned 43,676 shares of the company’s stock, valued at $5,365,596.60. This represents a 55.12% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 94,646 shares of company stock valued at $11,311,286. 0.27% of the stock is owned by insiders.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.